ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 61 filers reported holding ALPINE IMMUNE SCIENCES INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,660 | +11.4% | 1,193,030 | 0.0% | 0.59% | +54.2% |
| Q2 2023 | $12,264 | +33.2% | 1,193,030 | 0.0% | 0.38% | -30.5% |
| Q1 2023 | $9,210 | +5.0% | 1,193,030 | 0.0% | 0.55% | +11.9% |
| Q4 2022 | $8,769 | -99.9% | 1,193,030 | 0.0% | 0.49% | +33.2% |
| Q3 2022 | $8,590,000 | +70.2% | 1,193,030 | +101.2% | 0.37% | +35.9% |
| Q2 2022 | $5,047,000 | -5.1% | 593,030 | 0.0% | 0.27% | +21.1% |
| Q1 2022 | $5,319,000 | -35.2% | 593,030 | 0.0% | 0.22% | 0.0% |
| Q4 2021 | $8,213,000 | +29.8% | 593,030 | 0.0% | 0.22% | +57.0% |
| Q3 2021 | $6,328,000 | +18.6% | 593,030 | 0.0% | 0.14% | +31.5% |
| Q2 2021 | $5,337,000 | -15.1% | 593,030 | 0.0% | 0.11% | -2.7% |
| Q1 2021 | $6,286,000 | -15.9% | 593,030 | 0.0% | 0.11% | -30.6% |
| Q4 2020 | $7,472,000 | +43.3% | 593,030 | 0.0% | 0.16% | +26.0% |
| Q3 2020 | $5,213,000 | – | 593,030 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |